Request Free Legal Consultation
If you or a loved one has been diagnosed with mesothelioma or another asbestos-related disease, contact us for a free, no-obligation consultation.
THE SOKOLOVE PROMISE
If we find that we can move forward with your case, we'll start working right away so you don't have to waste precious time.
Phase II
Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma
Phase II, Phase III
Location:
Pittsburg, PA: Merck and Company, Incorporated
Trial Summary:
This is a Phase III a study which incorporates an initial Phase II component to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug suberoylanilide hydroxamic acid, in the treatment of advanced malignant pleural Mesothelioma.
Contact Information:
Ph: 1-888-577-8839
For Additional Information, Click Here
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
Phase II
Location:
Boston, MA: Dana-Farber/Brigham and Women's Cancer Center
Trial Summary:
The purposes of this study are: to determine the feasibility of administering adjuvant cisplatin plus ALIMTA to patients who undergo surgery with heated cisplatin during surgery; to determine the effects (good and bad) of this combined modality approach in patients with mesothelioma; to evaluate cisplatin effects by determining where it goes and how it is excreted in the body from the collection of tissues and cisplatin samples; to collect and analyze discarded samples of mesothelioma tumor during surgery to help determine the genetic make-up of the disease.
Contact Information:
David Sugarbaker, M.D.
Ph: 617-732-5004
Email: .(JavaScript must be enabled to view this email address)
For Additional Information, Click Here
Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery
Phase II
Location:
Multiple Locations
Trial Summary:
Primary Objective:
- Determine the objective response rate in patients with malignant pleural, peritoneal, or tunica vaginalis mesothelioma that is not amenable to curative surgery who are treated with AZD2171.
Secondary Objectives:
- Determine the progression-free survival of patients treated with AZD2171.
- Determine the toxicity experienced by patients treated with AZD2171.
- Determine median and overall survival of patients treated with AZD2171.
Contact Information:
Please see additional information
For Additional Information, Click Here
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Phase II
Location:
Dallas, TX: Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center – Dallas
Trial Summary:
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
Contact Information:
Jonathan E Dowell, MD
Ph: 214-648-4180
Email: .(JavaScript must be enabled to view this email address)
Erin Fenske
Ph: 214-648-7097
Email: .(JavaScript must be enabled to view this email address)
For Additional Information, Click Here
Phase II Study of Dasatinib in Patients With Previously Treated Malignant Mesothelioma
Phase II
Location:
Multiple Locations
Trial Summary:
The primary objective is to determine the rate of progression-free survival (PFS) at 24 weeks (or 5.5 months) in patients with malignant mesothelioma treated with dasatinib.
Contact Information:
Please see additional information
For Additional Information, Click Here
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Phase II
Location:
Chicago, IL: University of Chicago Cancer Research Center
New York, NY: NYU Cancer Institute at New York University Medical Center
Trial Summary:
Milataxel is a new taxane that may have several advantages over the currently available taxanes. The current study is designed to determine the response rate of oral Milataxel in patients with malignant Mesothelioma. The study specifically targets patients who have recurring or progressive disease following previous chemotherapy.
Contact Information:
University of Chicago Cancer Research Center:
Sarah Mauro
Ph: 773-834-3263
Email: .(JavaScript must be enabled to view this email address)
NYU Cancer Institute at New York University Medical Center:
Harvey Pass, M.D.
Ph: 212-731-5414
Email: .(JavaScript must be enabled to view this email address)
For Additional Information, Click Here
Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma
Phase II
Location:
New York, NY: Memorial Sloan-Kettering Cancer Center
Trial Summary:
For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including damage to the lung (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. This type of radiation therapy specifically targets the lining of the lung, where you have your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is to test the safety and toxicity of standard chemotherapy followed by IMRT.
Contact Information:
Kenneth Rosenzweig, MD
Email: .(JavaScript must be enabled to view this email address)
Lee Krug, MD
Email: .(JavaScript must be enabled to view this email address)
For Additional Information, Click Here
An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma
Phase II
Location:
Multiple Locations
Trial Summary:
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
Contact Information:
Please see additional information
For Additional Information, Click Here
Phase II Study of Everolimus in Patients With Unresectable Malignant Pleural Mesothelioma
Phase II
Location:
Multiple Locations
Trial Summary:
Primary Objective:
- To determine the 4-month progression-free survival in patients with unresectable malignant pleural mesothelioma treated with everolimus.
Secondary Objectives:
- To determine the response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate (response or stable disease) in patients with measurable disease by RECIST and modified RECIST criteria.
- To determine overall survival of these patients.
- To evaluate the frequency and severity of toxicities associated with this treatment regimen.
Contact Information:
Please see additional information
For Additional Information, Click Here
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Phase II
Location:
New York, NY: Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
Trial Summary:
Oxaliplatin (ELOXATIN®) is an organoplatinum complex which exerts its cytotoxic effect chiefly through inhibition of tumoral DNA synthesis and repair, leading to cellular apoptosis. The antiproliferative activity of oxaliplatin has been shown to approximate that of cisplatin or carboplatin in different tumor types. This is a phase II clinical trial of Oxaliplatin (ELOXATIN®) plus gemcitabine as first or secondline chemotherapy for patients with malignant pleural or peritoneal mesothelioma. This study aims to determine the objective tumor response rate for Oxaliplatin plus gemcitabine given every 14 days in patients with malignant pleural mesothelioma and/or malignant peritoneal mesothelioma who have no more than one prior chemotherapy regimen.
Contact Information:
Lilian Batista
Ph: 212-305-6837
Email: .(JavaScript must be enabled to view this email address)
Evelyn Reyes
Ph: 212-305-3846
Email: .(JavaScript must be enabled to view this email address)
For Additional Information, Click Here
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Phase II
Location:
New York, NY: Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
Trial Summary:
The primary objective of the study is to determine the overall 1 year survival rate of the two combined arms. Current surgical and/or chemotherapeutic approaches for malignant pleural mesothelioma are unsatisfactory and have not been shown to significantly prolong survival, and often lead to worsened pulmonary function and quality of life. A prospective trial of trimodal (surgery, pleural chemotherapy, and pleural radiation) therapy will be investigated to see if it can improve the overall 1 year survival in patients with malignant pleural mesothelioma.
Contact Information:
Lilian Batista
Ph: 212-305-6837
Email: .(JavaScript must be enabled to view this email address)
Evelyn Reyes
Ph: 212-305-3846
Email: .(JavaScript must be enabled to view this email address)
For Additional Information, Click Here
Become a Fan on Facebook 